LT3966207T - Fenilaminopirimidino amidai, kaip autofagijos inhibitoriai ir jų panaudojimo būdai - Google Patents
Fenilaminopirimidino amidai, kaip autofagijos inhibitoriai ir jų panaudojimo būdaiInfo
- Publication number
- LT3966207T LT3966207T LTEPPCT/US2020/032087T LTUS2020032087T LT3966207T LT 3966207 T LT3966207 T LT 3966207T LT US2020032087 T LTUS2020032087 T LT US2020032087T LT 3966207 T LT3966207 T LT 3966207T
- Authority
- LT
- Lithuania
- Prior art keywords
- phenylaminopyrimidine
- amide
- methods
- autophagy inhibitors
- autophagy
- Prior art date
Links
- -1 Phenylaminopyrimidine amide Chemical class 0.000 title 1
- 239000012822 autophagy inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962846258P | 2019-05-10 | 2019-05-10 | |
US201962846251P | 2019-05-10 | 2019-05-10 | |
US201962911730P | 2019-10-07 | 2019-10-07 | |
US201962911728P | 2019-10-07 | 2019-10-07 | |
PCT/US2020/032087 WO2020231806A1 (en) | 2019-05-10 | 2020-05-08 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3966207T true LT3966207T (lt) | 2023-12-11 |
Family
ID=73046797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2020/032087T LT3966207T (lt) | 2019-05-10 | 2020-05-08 | Fenilaminopirimidino amidai, kaip autofagijos inhibitoriai ir jų panaudojimo būdai |
Country Status (23)
Country | Link |
---|---|
US (2) | US11530206B2 (lt) |
EP (2) | EP3966207B1 (lt) |
JP (1) | JP2022531801A (lt) |
KR (1) | KR20220008873A (lt) |
CN (1) | CN114127057A (lt) |
AU (2) | AU2020275392B2 (lt) |
BR (1) | BR112021022504A2 (lt) |
CA (1) | CA3139708A1 (lt) |
CL (1) | CL2021002952A1 (lt) |
CO (1) | CO2021016768A2 (lt) |
DK (1) | DK3966207T3 (lt) |
FI (1) | FI3966207T3 (lt) |
IL (1) | IL287787A (lt) |
LT (1) | LT3966207T (lt) |
MX (1) | MX2021013661A (lt) |
PE (1) | PE20220597A1 (lt) |
PL (1) | PL3966207T3 (lt) |
PT (1) | PT3966207T (lt) |
RS (1) | RS65019B1 (lt) |
SG (1) | SG11202112336PA (lt) |
SI (1) | SI3966207T1 (lt) |
TW (1) | TW202108573A (lt) |
WO (1) | WO2020231806A1 (lt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3790551A4 (en) | 2018-05-07 | 2022-03-09 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
EP3902547B1 (en) | 2018-12-28 | 2023-09-20 | Deciphera Pharmaceuticals, LLC | Csf1r inhibitors for use in treating cancer |
JP2022517222A (ja) | 2019-01-10 | 2022-03-07 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
FI3966207T3 (fi) | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Autofagian fenyyliaminopyrimidiiniamidi-inhibiittoreita ja menetelmiä niiden käyttämiseksi |
EP4295846A3 (en) | 2019-05-10 | 2024-02-28 | Deciphera Pharmaceuticals, LLC | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
MX2021015628A (es) | 2019-06-17 | 2022-04-18 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. |
KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
KR20220071193A (ko) | 2019-08-29 | 2022-05-31 | 미라티 테라퓨틱스, 인크. | Kras g12d 억제제 |
MX2022003537A (es) | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Terapias de combinacion. |
BR112022012106A2 (pt) | 2019-12-20 | 2022-09-20 | Mirati Therapeutics Inc | Inibidores de sos1 |
AU2020419197B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
CN115243681A (zh) | 2019-12-30 | 2022-10-25 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
US11912668B2 (en) | 2020-11-18 | 2024-02-27 | Deciphera Pharmaceuticals, Llc | GCN2 and perk kinase inhibitors and methods of use thereof |
CN117545751A (zh) * | 2021-04-07 | 2024-02-09 | 生命爱科 | 作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途 |
TW202332448A (zh) * | 2021-11-15 | 2023-08-16 | 美商艾瑞斯卡公司 | 噻吩ulk1/2抑制劑及其用途 |
WO2024050351A1 (en) * | 2022-09-02 | 2024-03-07 | Deciphera Pharmaceuticals, Llc | Combination of dcc-3116 and mapkap pathway inhibitors for use in the treatment of cancer |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
GB9910807D0 (en) | 1999-05-10 | 1999-07-07 | Prometic Biosciences Limited | Novel detoxification agents and their use |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
US7276510B2 (en) | 2000-05-08 | 2007-10-02 | Janssen Pharmaceutica, Inc. | HIV replication inhibitors |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
WO2003002544A1 (en) | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003032997A1 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
JP4072615B2 (ja) | 2002-03-05 | 2008-04-09 | 独立行政法人産業技術総合研究所 | 配位子を有する複素環化合物及びその製造方法、及びこの複素環化合物を用いる金属元素の固定化膜 |
AU2003288198A1 (en) | 2002-11-28 | 2004-06-18 | Schering Aktiengesellschaft | CHK-,PDK- and AKT-inhibitory pyrimidines, their production and use as pharmaceutical agents |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
JP2007526894A (ja) | 2003-07-16 | 2007-09-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲンシンターゼキナーゼ3インヒビターとしてのトリアゾロピリミジン誘導体 |
DK1656372T3 (da) | 2003-07-30 | 2013-07-01 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme |
ES2365223T3 (es) | 2003-08-07 | 2011-09-26 | Rigel Pharmaceuticals, Inc. | Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos. |
EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
MXPA06014129A (es) | 2004-06-04 | 2007-03-07 | Arena Pharm Inc | Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos. |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
EP2942349A1 (en) | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
US8748627B2 (en) | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
AU2007254491A1 (en) | 2006-05-15 | 2007-11-29 | Irm Llc | Compositions and methods for FGF receptor kinases inhibitors |
US20070293494A1 (en) | 2006-06-15 | 2007-12-20 | Djung Jane F | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
CN101611035A (zh) | 2006-12-28 | 2009-12-23 | 大正制药株式会社 | 吡唑并嘧啶化合物 |
CA2684666A1 (en) | 2007-04-20 | 2008-11-20 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
CN101910151A (zh) | 2007-10-22 | 2010-12-08 | 先灵公司 | 双环杂环衍生物及其作为gpr119活性调节剂的用途 |
US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
EP2365752B1 (en) | 2008-10-29 | 2014-09-24 | Deciphera Pharmaceuticals, Llc | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
SG181965A1 (en) | 2009-12-30 | 2012-08-30 | Avila Therapeutics Inc | Ligand-directed covalent modification of protein |
US8569319B2 (en) | 2010-04-29 | 2013-10-29 | Deciphera Pharmaceuticals, LLS | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US20120058985A1 (en) | 2010-04-29 | 2012-03-08 | Deciphera Pharmaceuticals, Llc | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities |
CA2827171C (en) | 2011-02-17 | 2019-04-09 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
EP2782577A4 (en) | 2011-11-22 | 2015-11-11 | Deciphera Pharmaceuticals Llc | PYRIDONAMIDES AND ANALOGUES WITH ANTIBODY AND ANTIPROLIFERATIVE EFFECT |
MX349556B (es) | 2011-11-29 | 2017-08-03 | Genentech Inc | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). |
WO2013079495A1 (en) | 2011-11-29 | 2013-06-06 | F. Hoffmann-La Roche Ag | 2-(phenyl or pyrid-3-yl) aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
EP2785381B1 (en) | 2011-11-30 | 2016-05-18 | F.Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
US9187474B2 (en) | 2012-03-07 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
EP2888256A4 (en) | 2012-08-24 | 2016-02-17 | Univ Texas | HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES |
WO2014145015A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145025A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
EP2968287B1 (en) | 2013-03-15 | 2020-06-24 | Deciphera Pharmaceuticals, LLC | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
US9193719B2 (en) | 2013-03-15 | 2015-11-24 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
US9309224B2 (en) | 2013-03-15 | 2016-04-12 | Deciphera Pharmaceuticals, Llc. | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145004A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用 |
WO2015006492A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
WO2015039613A1 (zh) | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
AU2014323777C1 (en) | 2013-09-18 | 2018-04-26 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of BTK and/or JAK3 kinases |
PT3057943T (pt) | 2013-10-18 | 2018-07-24 | Eisai R&D Man Co Ltd | Inibidores de fgfr4 pirimidina |
PT3060550T (pt) | 2013-10-21 | 2019-08-27 | Merck Patent Gmbh | Compostos de heteroarilo como inibidores de btk e utilizações dos mesmos |
US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
US20150284341A1 (en) | 2014-04-07 | 2015-10-08 | Catylix, Inc. | Fluoroalkyl-substituted derivatives of pyridine, pyrimidine, and pyrazine |
CA2959347C (en) | 2014-08-25 | 2023-03-07 | Salk Institute For Biological Studies | Ulk1 inhibitors and methods using same |
CN108348779A (zh) | 2015-08-02 | 2018-07-31 | H·李·莫菲特癌症中心研究有限公司 | Ack1/tnk2酪氨酸激酶的抑制剂 |
WO2017066428A1 (en) | 2015-10-13 | 2017-04-20 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Brd4-kinase inhibitors as cancer therapeutics |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
RU2019129727A (ru) | 2017-02-28 | 2021-03-30 | Зэ Дженерал Хоспитал Корпорэйшн | Применения пиримидопиримидинонов в качестве ингибиторов sik |
KR20220143152A (ko) | 2017-05-30 | 2022-10-24 | 데시페라 파마슈티칼스, 엘엘씨. | 혈소판 유래 성장 인자 수용체 알파의 유전적 이상과 연관된 암 치료를 위한 1-[4-브로모-5-[1-에틸-7-(메틸아미노)-2-옥소-1,2-다이히드로-1,6-나프티리딘-3-일]-2-플루오로페닐]-3-페닐우레아 및 유사체의 용도 |
EA202091763A1 (ru) | 2018-01-31 | 2020-12-14 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия для лечения мастоцитоза |
CN112189012B (zh) | 2018-04-10 | 2024-02-13 | 神经孔疗法股份有限公司 | 作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物 |
EP3902547B1 (en) | 2018-12-28 | 2023-09-20 | Deciphera Pharmaceuticals, LLC | Csf1r inhibitors for use in treating cancer |
EP4295846A3 (en) | 2019-05-10 | 2024-02-28 | Deciphera Pharmaceuticals, LLC | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
FI3966207T3 (fi) | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Autofagian fenyyliaminopyrimidiiniamidi-inhibiittoreita ja menetelmiä niiden käyttämiseksi |
MX2021015628A (es) | 2019-06-17 | 2022-04-18 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. |
-
2020
- 2020-05-08 FI FIEP20729420.8T patent/FI3966207T3/fi active
- 2020-05-08 AU AU2020275392A patent/AU2020275392B2/en active Active
- 2020-05-08 WO PCT/US2020/032087 patent/WO2020231806A1/en active Application Filing
- 2020-05-08 EP EP20729420.8A patent/EP3966207B1/en active Active
- 2020-05-08 PT PT207294208T patent/PT3966207T/pt unknown
- 2020-05-08 SG SG11202112336PA patent/SG11202112336PA/en unknown
- 2020-05-08 US US16/870,384 patent/US11530206B2/en active Active
- 2020-05-08 KR KR1020217040559A patent/KR20220008873A/ko active Search and Examination
- 2020-05-08 SI SI202030312T patent/SI3966207T1/sl unknown
- 2020-05-08 EP EP23206773.6A patent/EP4342469A2/en active Pending
- 2020-05-08 PE PE2021001870A patent/PE20220597A1/es unknown
- 2020-05-08 BR BR112021022504A patent/BR112021022504A2/pt unknown
- 2020-05-08 CN CN202080049700.3A patent/CN114127057A/zh active Pending
- 2020-05-08 DK DK20729420.8T patent/DK3966207T3/da active
- 2020-05-08 RS RS20231266A patent/RS65019B1/sr unknown
- 2020-05-08 PL PL20729420.8T patent/PL3966207T3/pl unknown
- 2020-05-08 TW TW109115468A patent/TW202108573A/zh unknown
- 2020-05-08 JP JP2021566469A patent/JP2022531801A/ja active Pending
- 2020-05-08 CA CA3139708A patent/CA3139708A1/en active Pending
- 2020-05-08 LT LTEPPCT/US2020/032087T patent/LT3966207T/lt unknown
- 2020-05-08 MX MX2021013661A patent/MX2021013661A/es unknown
-
2021
- 2021-11-02 IL IL287787A patent/IL287787A/en unknown
- 2021-11-09 CL CL2021002952A patent/CL2021002952A1/es unknown
- 2021-12-10 CO CONC2021/0016768A patent/CO2021016768A2/es unknown
-
2022
- 2022-06-06 US US17/833,272 patent/US20230039712A1/en active Pending
-
2023
- 2023-10-17 AU AU2023251416A patent/AU2023251416A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3966207B1 (en) | 2023-11-01 |
EP4342469A2 (en) | 2024-03-27 |
CL2021002952A1 (es) | 2022-07-15 |
JP2022531801A (ja) | 2022-07-11 |
SI3966207T1 (sl) | 2023-12-29 |
KR20220008873A (ko) | 2022-01-21 |
AU2020275392B2 (en) | 2023-09-14 |
PL3966207T3 (pl) | 2024-03-04 |
CA3139708A1 (en) | 2020-11-19 |
PE20220597A1 (es) | 2022-04-22 |
BR112021022504A2 (pt) | 2022-04-12 |
FI3966207T3 (fi) | 2023-11-30 |
US11530206B2 (en) | 2022-12-20 |
CN114127057A (zh) | 2022-03-01 |
RS65019B1 (sr) | 2024-01-31 |
AU2020275392A1 (en) | 2021-12-02 |
SG11202112336PA (en) | 2021-12-30 |
AU2023251416A1 (en) | 2023-11-09 |
CO2021016768A2 (es) | 2022-04-08 |
US20230039712A1 (en) | 2023-02-09 |
TW202108573A (zh) | 2021-03-01 |
PT3966207T (pt) | 2023-12-20 |
EP3966207A1 (en) | 2022-03-16 |
US20200354352A1 (en) | 2020-11-12 |
MX2021013661A (es) | 2022-03-11 |
WO2020231806A1 (en) | 2020-11-19 |
DK3966207T3 (da) | 2023-12-18 |
IL287787A (en) | 2022-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287787A (en) | Phenylaminopyrimidine amide as autophagy inhibitors and methods of using them | |
IL287795A (en) | Heteroarylaminopyrimidine amide as autophagy inhibitors and methods of using them | |
IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
IL287768A (en) | kcnt1 inhibitors and methods of use | |
IL287751A (en) | kcnt1 inhibitors and methods of use | |
IL287973A (en) | acss2 inhibitors and methods of their use | |
IL288996A (en) | Aminopyrimidine amide autophagy inhibitors and methods of using them | |
IL276711A (en) | Arginase inhibitors and methods of using them | |
IL284640A (en) | PCSK9 inhibitors and methods of using them | |
IL284661A (en) | pcsk9 inhibitors and methods of using them | |
EP3986894A4 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | |
EP3846808A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
IL280924A (en) | Arginase inhibitors and methods of using them | |
EP3959197A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
IL286149A (en) | Caspase inhibitors and methods of using them | |
IL285108A (en) | Arginase inhibitors and methods of using them | |
IL264854A (en) | Spt5 inhibitors and methods of use thereof |